New pill targets brain inflammation in Parkinson's fight
NCT ID NCT07142044
Summary
This early-stage study is testing a new oral drug called EC5026 to see if it is safe and reaches the brain in adults with Parkinson's Disease. Over 28 days, 18 participants will take either the drug or a placebo pill, with frequent clinic visits for blood tests, spinal fluid checks, and symptom questionnaires. The main goal is to check safety and drug levels, while also exploring if it helps improve Parkinson's symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California Davis
RECRUITINGSacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.